Author | Therapy type | Therapy | CTA target | Response |
Chawla et al *abstract60 | Vaccine | CMB305 (LV305+G305) | NY-ESO-1 | No change in OS. |
Somaiah et al57 | Vaccine | LV305 | NY-ESO-1 | 1/13 patients with PR, 6/13 having SD. |
Ishihara et al61 | Vaccine | CHP-NYESO-MIS416 | NY-ESO-1 | 1/4 had SD with rest having PD. |
Kawaguchi et al62 | Vaccine | SYT-SSX | SYT-SSX | 6/12 patients in protocol B had SD. |
Butler et al *abstract71 | TCR | TBI-1301 | NY-ESO-1 | 2/9 patients had PR and 5/9 had SD. |
Robbins et al68 | TCR | 1G4-α95:LY | NY-ESO-1 | 11/18 patients had PR. |
D’Angelo et al69 | TCR | NY-ESO-1c259 (SPEAR T Cell) | NY-ESO-1 | 6/12 patients had PR. |
Ramachandran et al81 | TCR | NY-ESO-1c259 (SPEAR T Cell) | NY-ESO-1 | Had three cohorts for 30 total patients and only 2/30 had PD. |
Hong et al *abstract74 | TCR | ADP-A2M4 | MAGE-A4 | In cohort 3 (N=28) all seven PR were from SS patients. |
Morgan et al76 | TCR | TCR (unnamed) | MAGE-A3 | Only 1 SS patient. Patient experienced PR. |
CTA, cancer testis antigen; OS, overall survival; PD, progressive disease; PR, positive response; SD, stable disease; SS, synovial sarcoma; TCR, T-cell receptor.